This drug sounds promising. Sounds like it will be more effective than abilify at least. Do you know when it’s supposed to release if it passes phase 3?
My guess is 3+ years for trials, analysis and application review.
Article
I remember this one from like SIX and a half years ago. The company was first pursuing it for pulmonary hypertension. I don’t know what became of that.
But I remember it because of this article which mentions a high rate of “remission level response.”
RP5063 global phase 2 clinical trial results showed a robust remission level efficacy for acute schizophrenia in addition to promising efficacy signals for comorbid conditions cognition impairment and mood disorders. RP5063 showed a very good safety and tolerability profile with no weight gain, metabolic, cardiac or movement side effects, leading to good acceptance and compliance with the treatment.
Better late than never!